SCHEMBL21363824

SCHEMBL21363824

Cc1ccc(-c2ccc(-c3cccc(F)c3)cc2F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.47
ESR2 Q92731 1/20 0.47
TNKS2 Q9H2K2 1/20 0.45
ACHE P22303 1/20 0.45
PDE3B Q13370 2/20 0.44
PDE3A Q14432 2/20 0.44
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
ALOX15 P16050 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
NFKB1 P19838 1/20 0.43
CASP1 P29466 1/20 0.43
CASP3 P42574 1/20 0.43
NFKB2 Q00653 1/20 0.43
KMT2A Q03164 1/20 0.43
RELA Q04206 1/20 0.43
SENP8 Q96LD8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19308530 0.87 TAAR1 (0.52) TAAR1ESR2PDE3BPDE3AMAPT
SCHEMBL12384873 0.87 TAAR1 (0.55) TAAR1ESR2TNKS2PDE3BPDE3A
SCHEMBL4567630 0.87 PDE3B (0.50) ESR2ACHEPDE3BPDE3AMAPT
SCHEMBL14864492 0.86 NFE2L2 (0.58) TAAR1ESR2PDE3BPDE3ARELA
SCHEMBL10091190 0.85 MAPT (0.49) PDE3BPDE3AMAPTSMN1; SMN2NPC1
SCHEMBL10091182 0.85 MAPT (0.49) PDE3BPDE3AMAPTSMN1; SMN2NPC1
SCHEMBL170435 0.85 PDE3B (0.49) ESR2ACHEPDE3BPDE3AMAPT
SCHEMBL10091196 0.85 TAAR1 (0.63) TAAR1ESR2TNKS2ACHEMAPT
SCHEMBL5543756 0.85 TAAR1 (0.63) TAAR1ESR2TNKS2ACHEMAPT
SCHEMBL10091329 0.84 ACHE (0.47) TAAR1ESR2TNKS2ACHEPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284180-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF ACCRO BIOSCIENCE (HK) LIMITED (HK) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284180-A1 HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF LITAF, BAX, TNF TAAR1 4136/4885ESR2 2525/4885TNKS2 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.